16.2.2 Protocol Deviations

Severity	Participants Affected	Deviation Description
Minor	38, 40, 48	According to Section 5.13.4.2 of the protocol, "Samples for plasma cotinine will be collected into one 4 ml plastic K2EDTA (lavender top) vacutainer tube. Immediately following the collection, blood samples will be gently mixed by inverting the tubes 8 times. The samples may be kept at ambient temperature prior to centrifuge, and will be centrifuged at 1000 - 1300 RCF for 10 minutes at 5°C within 60 minutes of collection. After centrifugation, approximately 1 ml of plasma will be transferred into 2 appropriately labeled 3.5 ml polypropylene screw top tubes." Group 1: On Day 15 for Group 1, a short sample for Subject 38 was obtained for the H1029A aliquot for the 341hr time point. On Day 16 for Group 1, a short sample for Subject 38 was obtained for the BN1029 aliquot for the 360.17hr time point. On Day 16 for Group 1, a short sample for Subject 1 was obtained for the BN1029 aliquot for the 360.25hr time point. Group 2: On Day 1 for Group 2, a short sample for Subject 42 was obtained for the H1029A aliquot for the -19.00hr time point. Group 4: On Day 44 for Group 4, a short sample for Subject 48 was obtained for the BN1029 aliquot for the 360.17hr time point.
Minor	2, 3, 39, 41	In Section 5.13.3 of the protocol, "Prior to the first urine sample collection, each subject will be instructed as to the urine collection methods. All urine during an interval is to be collected and

<table>
<tr><th>Severity</th><th>Participants Affected</th><th>Deviation Description</th></tr>
<tr><td></td><td></td><td>subjects will be asked to empty their bladder before the start of the urine collection period."

On Day -1, Subject 41 spilled about 667.1 g of urine in error when on collection. There was 66.7 g of urine left in the container after the spill.</td></tr>
<tr><td>Minor</td><td>10, 40</td><td>According to Section 5.13.6 of the Protocol, "One 4 ml blood sample for plasma nicotine analysis will be drawn into a plastic K2-EDTA (lavender top) vacutainer tube at -5, 2, 5, 7, 10, 12, 15, 20, 30, 45, 60, 90, 120, 150, and 180 minutes relative to the start of cigarette smoking."

The following participants had deviations for the following time points.
<table>
<tr><th>Participant</th><th>Group</th><th>Period</th><th>Time Point</th><th>Sample missed due to…</th></tr>
<tr><td>40</td><td>2</td><td>1</td><td>0.2</td><td>Adverse event</td></tr>
<tr><td>40</td><td>2</td><td>1</td><td>0.25</td><td>Adverse event</td></tr>
<tr><td>10</td><td>4</td><td>1</td><td>0.08</td><td>Difficult Venipuncture</td></tr>
</table>
</td></tr>
<tr><td>Major</td><td>7, 44</td><td>According to Section 5.13.3 of the protocol, "The urine samples collected during a single 24-hour period will be pooled together and weighed. The pooled samples will be thoroughly mixed before providing aliquots for analyses."

On Day 15 of Group 2, Subject 44's urine was pooled into Subject 7's 24-hour pooling container in error. Subject 7 will not have 24-hour urine aliquots for analysis due to this error.</td></tr>
<tr><td>Major</td><td>2, 3, 39</td><td>In Section 5.13.3 of the Protocol, "Prior to the first urine sample collection, each subject will be instructed as to the urine collection methods. All urine during an interval is to be collected and subjects will be asked to empty their bladder before the start of the urine collection period."

During the Week 6, 24 hour urine collection for Group 1 on 06-Sep-2018, at approximately 12:45 the pooling jugs for Subjects 3-10 (001-010), 2-8 (001-008), and 39-11 (001-011) were discarded in error. New urine pooling jugs were created for these subjects and staff continued to collect their voids until the end of the interval. These samples were destroyed according to 22nd Century as they can't be used for primary analysis.</td></tr>
</table>

Severity	Participants Affected	Deviation Description
Minor	7	According to the Schedule of Events, "Subjects will participate in the study for a period of 7 weeks after the start of Week -1, with a follow-up call approximately 7 days after the last study visit. " At the 960 hr time point, the second attempted time of contact was not documented on data in error for Subject 7.
Minor	Group 2: 4, 5, 6, 7, 40-45 Group 4: 8-16, 46-54 Group 5: 17, 19, 20, 55, 58-65 Group 6: 21-25, 66, 67, 69, 70 Group 7: 147-152, 154, 155, 162-165	Per Celerion Standard Operations Procedures, raw data must be accurately recorded and managed. Protocol requirements must be documented as evidence that they were performed. For Group 2 on 16-AUG-2018 at 20:45, W2 Verification Raw data was not documented at time of event in error. For Group 2 on 16-AUG-2018 at 20:45, Dispense Canisters Raw data was not documented at time of event in error. For Group 2 on 12-SEP-2018 at 17:00, Dispense Diary Raw Data was not filled out at time of event in error. For Group 2 on 02-AUG-2018 at 08:20, Blood Collection Conditions Raw Data was not filled out at time of event in error. For Group 2 on 26-JUL-2018 at 07:00, Confiscate Nicotine Products Raw Data was not filled out at time of event in error. For Group 2 Sample Reconciliation Records for all time points, the H0001 transfer tube "Time In" was not documented at time of event in error. For Group 4 on 10-OCT-2018, W6 Verification Raw data was not documented at time of event in error.

Severity	Participants Affected	Deviation Description
		For Group 4 on 25-SEP-2018 at 07:45, Dispense Diary Raw Data was not filled out at time of event in error. For Group 4 on 25-SEP-2018 at 07:00, Collect Nicotine Products Raw Data was not filled out at time of event in error. For Group 5 on 24-OCT-2018, Blood Collection Conditions Raw Data was not filled out at time of event in error. For Group 5 on 25-OCT-2018, Symptom Driven Physical Raw Data was not filled out at time of event in error. For Group 5 on 05-SEP-2018, Usual Brand Cigarette documentation raw data was not filled out at time of event in error for all subjects except 57. For Group 5 on 09-OCT-2018, Usual Brand Cigarette documentation raw data was not filled out at time of event in error. For Group 5 on 05-SEP-2018, Return Nicotine Products raw data was not filled out at time of event in error. For Group 5 on 25-SEP-2018, Return Canisters for Used Cigarette Butts raw data was not filled out at time of event in error. For Group 6 on 30-OCT-2018, Turn in/Review Diary raw data was not filled out at time of event in error. For Group 6 on 30-OCT-2018, Dispense Canisters for Used Cigarette Butts raw data was not filled out at time of event in error.

Severity	Participants Affected	Deviation Description
		For Group 6 on 16-OCT-2018, Dispense Diary raw data was not filled out at time of event in error. For Group 6 on 17-SEP-2018, Dispense Diary raw data was not filled out at time of event in error. For Group 6 on 16-OCT-2018, W4 Assessment Verification Raw Data was not filled out at time of event in error. For Group 7 on 01-NOV-2018, Dispense Diary Raw Data was not filled out at time of event in error. For Group 7 on 15-NOV-2018, Dispense Diary Raw Data was not filled out at time of event in error. For Group 7 on 15-NOV-2018, Collect Test Compound Raw Data was not filled out at time of event in error. For Group 7 on 15-NOV-2018, Return Canisters for Used Cigarette Butts Raw Data was not filled out at time of event in error.
Minor	163	In Section 5.13.3 of the protocol, "Prior to the first urine sample collection, each subject will be instructed as to the urine collection methods. All urine during an interval is to be collected and subjects will be asked to empty their bladder before the start of the urine collection period." On Day -1, Subject 163 voided an estimated 250 mL of urine into the toilet in error.
Minor	58	According to Section 5.13.5 of the protocol, "During the puffing topography assessment, subjects will engage in a 1-hour ad libitum smoking session with their UB (Week -1) or the VLN (Weeks 2 and 6) cigarettes. In these sessions, subjects will smoke cigarettes with the mobile smoking puff analyzer (SPA-M; Sodim). The topography device will be monitored to ensure the device is actively recording during each session."

Severity	Participants Affected	Deviation Description
		On 26SEP2018, Subject 58-78's Sodim device was started after the administration of the first cigarette during ad libitum conditions in error.
Minor	18, 68, 146	According to Section 5.7 of the protocol, "At the end of the study, the following procedures will be performed: Review of AEs and concomitant medication use, vital signs, body weight, 12-lead ECG, Clinical Chemistry, hematology, and urinalysis, Symptom Driven Physical, and Provide smoking cessation information." Additional follow-up instructions our outlined in section 5.8, "The CRU will attempt to contact all subjects who participated in the study (including subjects who terminate the study early) using their standard procedures approximately 7 days after the last contact." At the start of Week 4, Subject 68 was discontinued for non-compliance to protocol restrictions. Neither Early Termination events nor follow-up phone call were completed after discontinuation because the subject didn't consent. At the start of Week 4, Subject 18 chose to drop from the study. Smoking cessation information was not provided upon early termination and the follow up phone call event was not completed for this subject in error. At the end of Week 6, Subject 146 chose to drop from the study. Neither Early Termination events nor follow-up phone call were completed after discontinuation because the subject didn't consent.
Minor	Group 1: 1-3, 36-39 Group 2:4, 5, 7, 40-45 Group 4:8-16, 46-54 Group 5:17, 19, 20, 55, 58-65 Group 6: 21-25, 66, 67, 69, 70 Group 7: 147-152, 154, 155, 162-165	According to Section 5.5 of GSOP.03.0012, "Relevant to the task they are performing, the PI/designee is responsible to ensure they have read and understand the most recent protocol and/or IP information, and document the reading of the appropriate documents in ClinQuick®." Protocol Amendment 1 dated 18-Jun-2018 was IRB approved on 27-Jul-2018 and the approval letter was dated 30-Jul-2018 Protocol Amendment 2 dated 20-Jul-2018 was IRB approved on 30-Jul-2018 and the approval letter was dated 30-Jul-2018.

Severity	Participants Affected	Deviation Description
		Please note that Protocol Amendment 1 and 2 were IRB approved and the IRB approval letters were sent to the site on the same day (30-Jul-2018). PCL dated 30-Oct-2018 was IRB approved on 06-Nov-2018 and the approval letter was dated 06-Nov-2018. Allen Hunt, MD—did not read/complete training in a timely manner for: • Amendment 1 Dated 18JUN2018 – IRB 30-Jul-2018 – trained – 01-Aug-2018 • Amendment 2 Dated 20-Jul-2018 – IRB 30-Jul-2018 – trained – 07-Aug-2018 • PCL dated 30OCT2018 – IRB 06-Nov-2018 – trained 20-Nov-2018 Natasha Wilson, APRN—did not read/complete training for or in a timely manner for: • Amendment Dated 18JUN2018 – IRB 30-Jul-2018 – not trained • Amendment 2 Dated 20-Jul-2018 – IRB 30-Jul-2018 – trained – 10-Aug-2018 • PCL dated 30OCT2018 – IRB 06-Nov-2018 – trained 27-Nov-2018 Robert Schwab, MD—did not read/complete training for or in a timely manner for: • Amendment Dated 18JUN2018 – IRB 30-Jul-2018 – not trained • Amendment 2 Dated 20-Jul-2018 – IRB 30-Jul-2018 – trained – 08-Aug-2018 • PCL dated 30OCT2018 – IRB 06-Nov-2018 – trained 19-Nov-2018 Philip Mathew, MD —did not read/complete training for or in a timely manner for: • Final Protocol09MAY2018; however, signed this protocol on 10-May-2018 • Protocol Amendment 1 Dated 18JUN2018; however, signed this amendment on 21-Jun-2018 • Amendment 2 Dated 20-Jul-2018 – IRB 30-Jul-2018 – trained 03-Aug-2018 • PCL dated 30OCT2018; however, signed this PCL on 02-Nov-2018

Severity	Participants Affected	Deviation Description
		• The 20-JUL-2018 Protocol Version wasn't signed until 24-SEP-2018. Between these dates, conduct was completed for Groups 3, 4, and 5. Lisa Mapson, PA —did not read/complete training in a timely manner for: • Amendment 1 Dated 18JUN2018 – IRB 30-Jul-2018 – trained 31-Jul-2018 • Amendment 2 Dated 20-Jul-2018 – IRB 30-Jul-2018 – trained 03-Aug-2018 • PCL dated 30OCT2018 – IRB 06-Nov-2018 – trained 20-Nov-2018 Charles Tomek, MD —did not read/complete training for or in a timely manner for: • Protocol Amendment 1 Dated 18JUN2018 – IRB 30-Jul-2018 – not trained • Amendment 2 Dated 20-Jul-2018 – IRB 30-Jul-2018 – trained – 03-Aug-2018 • PCL dated 30-Oct-2018 – IRB 06-Nov-2018 – trained 20-Nov-2018
Major	Group 1: 1-3, 36-39 Group 2:4-7, 40-45 Group 4:8-16, 18, 46-57 Group 5:17, 18, 19, 20, 55, 56-65 Group 6: 21-25, 66, 67, 69, 70 Group 7: 147-152, 154, 155, 162-165	According to Section 2 of GSOP.03.0009, "The current IRB/EC approved study-specific ICF must be distributed to each participant upon arrival for their initial screening appointment." The following deviations occurred relating to the administration of the ICF: At the time of screening on 02-JUL-2018, the protocol version dated 18-JUN-2018 was used in error to prepare for the administration of the Informed Consent to participants. The version of the protocol approved for use at this time was the version dated 09-MAY-2018. The correct IRB-approved ICF (13 Jun 2018, Revised 15-Jun-2018) was used to consent the subjects. At the time of screening on 23-JUL-2018, the protocol version dated 18-JUN-2018 was used in error to prepare for the administration of the Informed Consent to participants. The version of the protocol approved for use at this time was the version dated 09-MAY-2018. The correct IRB-approved ICF (13 Jun 2018, Revised 15-Jun-2018) was used to consent the subjects.
Minor	1, 11, 37, 52, 69, 70, 148, 151	According to Section 5.13.7.1 of the protocol, "Subjects will be provided with e-diaries to record their daily cigarette consumption, both when in clinical confinement during study visits

<table>
<tr><th>Severity</th><th>Participants Affected</th><th>Deviation Description</th></tr>
<tr><td></td><td></td><td>and during ambulatory periods. Questionnaires examining subjective effects will be completed using an electronic data collection system (Clinical Ink)."

The following participants failed to complete the Questionnaires at the required times listed below. Please note that the subject ID listed reflects their SID, not CLID. Screening ID numbers includes a leading "1" which is the site identifier code:

<table>
<tr><td>Subject</td><td>Diary Entry Date</td><td>Missing Data</td></tr>
<tr><td>1002</td><td>22-AUG-2019</td><td>Questionnaires</td></tr>
<tr><td>1003</td><td>22-AUG-2019</td><td>Questionnaires</td></tr>
<tr><td>1050</td><td>12-SEP-2019</td><td>Questionnaires</td></tr>
<tr><td>1086</td><td>17-SEP-2019</td><td>Questionnaires</td></tr>
<tr><td>1052</td><td>25-SEP-2019</td><td>Questionnaires</td></tr>
<tr><td>1096</td><td>16-OCT-2019</td><td>Questionnaires</td></tr>
<tr><td>1098</td><td>19-OCT-2019</td><td>Questionnaires</td></tr>
<tr><td>1101</td><td>19-OCT-2019</td><td>Questionnaires</td></tr>
<tr><td>1096</td><td>30-OCT-2019</td><td>Questionnaires</td></tr>
<tr><td>1098</td><td>01-NOV-2019</td><td>Questionnaires</td></tr>
<tr><td>1101</td><td>01-NOV-2019</td><td>Questionnaires</td></tr>
</table>
</td></tr>
<tr><td>Minor</td><td>43</td><td>According to Section 3.3.1 of the protocol, "All concomitant medications (and reasons for their use) taken by subjects during the study will be recorded and listed."

Subject 43 was instructed to take preparatory doses of acetaminophen, aspirin, and clopidogrel prior to surgical procedures as noted in the medical records received by Celerion. The subject is lost to follow up and, as such, compliance with these instructions cannot be verified.</td></tr>
<tr><td>Minor</td><td>25</td><td>According to section 5.13.3 of the Protocol, "The urine samples collected during a single 24-hour period will be pooled together and weighed. The pooled samples will be thoroughly mixed before providing aliquots for analyses."</td></tr>
</table>

Severity	Participants Affected	Deviation Description
		For the 323 - 347 24 hr Urine Collection Interval, Subject 25 reported that she spilled "quite a bit of urine from her urine container in error". The amount of urine spilled was not able to be identified.
Minor	47	According to Section 2.2 of GSOP.03.0001, "The PI/designee will be informed of the administration of protocol-approved over-the-counter (OTC) medications given in response to an AE (e.g., acetaminophen). This communication (with the PI/designee) will be documented in Progress Notes." On 13-SEP-2018, Subject 47 received Acetaminophen per the concomitant medication report, but no progress note was entered at time of administration in error.
Minor	147-152, 154, 155, 162-165	According to Section 2 of GSOP.03.0042, "The Clinical Laboratory results will be submitted to the Principal Investigator (PI)/designee for review. Clinically appropriate reference ranges will be established by each Clinical Laboratory for all tests performed. The PI/designee will document the review and assessment of the laboratory results either in ClinQuick® or by initialing/dating the hardcopy report. The PI/designee must accept the laboratory results prior to dosing the participant on study." On Day -1, the Check-In Drug screens were not reviewed the same day prior to the first administration of the VLN. This was reviewed the next day. There was no initial dose for this group as they didn't participate in PK or Topography. All participants had no outstanding findings on the drug screen.
Major	8	According to Section 5.13.5 of the protocol, “At clinic visits at the end of Weeks -1, 2, and 6, a randomly-selected subset of 18 nonmenthol and 18 menthol smoker subjects will complete a puffing topography evaluation session with either their UB (Week -1) or the VLN (Weeks 2 and 6) cigarettes.” During the clinic visit at the end of Week 6, an unknown error occurred during the topography event for Subject 001-029. According to the raw data, this subject smoked one cigarette using the topography device during the topography session however no topography data was able to be retrieved from the device upon completion of the event.
Minor	50	According to Section 5.13.5 of the protocol, "At clinic visits at the end of Weeks -1, 2, and 6, a

Severity	Participants Affected	Deviation Description
		randomly-selected subset of 18 nonmenthol and 18 menthol smoker subjects will complete a puffing topography evaluation session with either their UB (Week -1) or the VLN (Weeks 2 and 6) cigarettes." During the clinic visit at the end of Week 2, an unknown error occurred during the topography event for Subject 001-038. According to the raw data, this subject smoked two cigarettes using the topography device during the topography session. Upon completion of this event the topography data from the first cigarette smoked was able to be retrieved from the topography device however there was no data available for the second cigarette.
Minor	54	According to Section 5.5 of the protocol, product use will be recorded during all clinic visits. At End of Week 6, on 10-OCT-2018 at the Unrestricted Smoking Event at 08:00, the stop time was not documented in error for Subject 54 on two separate occurrences.
Minor	162	According to the Summary of Study Events, a color photocopy of the front and back of the subject's UB cigarette pack along with a ruler should be taken at Screening, th eStart of Week -1, and the End of Weeks -1, 2, 4, & 6. At the End of Week 4, on 01-NOV-2018 for the 647.50 hr time point, Subject 162 (001-112) didn't have their Usual Brand Cigarettes photocopied in error.
Minor	25	According to Section 2.1 of the protocol, "During Week -1 (all subjects) and all subsequent weeks (subjects randomized to continue smoking UB cigarettes) subjects will be asked not to change their UB cigarette brand or flavor." Subject 25 (001-095) switched usual brand product use from Menthol Pyramid Gold to Menthol Seneca Green during the study.
Minor	146, 147, 148, 149, 150, 152, 154, 155, 162, 163, 165	According to Section 5.7 outlining the End-of-Study Procedures to be completed, subjects are to be provided smoking cessation information at the End of Week 6 visit or on Early Discontinuation. Subjects 146, 147, 148, 149, 150, 152, 154, 155, 162, 163, and 165 were not provided the smoking cessation information at the End of Study Visit in error.

Severity	Participants Affected	Deviation Description
Minor	17, 18, 19, 20, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65	According to Section 11 of the Sample Handling Manual, "All urine voided by each subject will be collected throughout the 24-hour interval from approximately 7:00 pm through approximately 7:00pm the following evening." The end of the Week -1 urine collection interval for Subjects 17, 18, 19, 20, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, and 65 started and ended early in error. Per email correspondence, the collection was to have started and ended within +/- 30 minutes of 7:00 pm.

Subject ID	Date of Deviation	Deviation Category	Description of Deviation	If Reportable: Date Submitted to IRB or NA	Major Deviation Y/N	Comments
002-058	2-Aug-18	Eligibility	Subject was randomized with eCO Results of 8 ppm at the Start of Week -1 visit (should have been greater than 10 ppm to meet inclusion criteria, per protocol). Sponsor was notified and subject was allowed to continue.		Y	SITE to add IRB notification date/adjust
002-115	21-Sep-18	Subject Compliance	Subject was an Early Termination due to non-compliance. Subject did not return 5 sealed packs of VLN Menthol Product on 21Sep2018 at the End of Week 2 visit.	NA	N	
002-115	21-Sep-18	Subject Compliance	Subject did not return for Early Termination procedures or complete Follow up phone call and was Lost to Follow up.	NA	N	
002-115	6-Sep-18	Subject Compliance	Subject did not return 3 small empty canisters at End of Week -1.	NA	N	
002-014	28-Aug-18	Study Procedures	Pregnancy Test was completed on a male subject at the End of Week 6 visit.	NA	N	
002-126	6-Oct-18	Study Schedule Compliance	End of Week 4 visit Out of Window, No Show on 05Oct2018 visit, was rescheduled to 06Oct2018	NA	N	
002-249	7-Nov-18	Study Procedures	Subject did not rest 10 minutes prior to ECG at Screening.	NA	N	

002-075	27-Sep-18	Subject Compliance	Subject was an Early Termination due to non-compliance. Follow-up call was not completed.	NA	N	
002-075	22-Aug-18	Subject Compliance	Subject was an Early Termination due to non-compliance. Subject did not return 1 pack of VLN Menthol at the End of Week 2 visit.	NA	N	
002-009	14-Aug-18	Study Procedures	Subject was an Early Termination due to positve UDS. Follow-up call was not completed.	NA	N	
002-086	31-Aug-18	Subject Compliance	Subject did not bring 1 canister back at the End of Week -1 visit.	NA	N	
002-086	15-Sep-18	Subject Compliance	Subject did not return 14 empty packs of VLN Non-Menthol at the End of Week 2 visit.	NA	N	
002-088	15-Sep-18	Subject Compliance	Subject did not return 8 empty packs of VLN Menthol at the End of Week 2 visit.	NA	N	
002-099	15-Sep-18	Subject Compliance	Subject did not return 10 empty packs of VLN Non-Menthol at the End of Week 2 visit.	NA	N	
002-108	15-Sep-18	Subject Compliance	Subject did not return 36 empty packs of VLN Non-Menthol at the End of Week 2 visit.	NA	N	
002-113	21-Sep-18	Subject Compliance	Subject did not return 1 pack of VLN Menthol at the End of Week 2 visit.	NA	N	
002-113	22-Sep-18	Subject Compliance	Subject did not return 17 packs of VLN Menthol at the End of Week 2 visit. Subject was an Early Termination and was lost to follow-up.	NA	N	

002-113	22-Sep-18	Subject Compliance	Subject did not return for Early Termination procedures or complete Follow up phone call after multiple contact attempts. Subject was Lost to Follow up.	NA	N	
002-119	21-Sep-18	Subject Compliance	Subject did not return 5 empty packs of VLN Menthol at the End of Week 2 visit.	NA	N	
002-136	21-Sep-18	Subject Compliance	Subject did not return 5 empty packs of VLN Non-Menthol at the End of Week 2 visit.	NA	N	
002-136	26-Oct-18	Subject Compliance	Subject did not return multiple contact attempts and unable to complete Follow-up phone call.	NA	N	
002-039	23-Jul-18	Subject Compliance	Subject did not complete eDiary Questionnaire at the End of Week -1 visit.	NA	N	
002-166	27-Sep-18	Informed Consent	Subject did not initial and date Healthcare Provider box on page 19 of Informed Consent.	N/A	N	IRB does not want reported
002-219	11-Oct-18	Informed Consent	Subject did not complete the Healthcare Provider box on page 19 of Informed Consent.	N/A	N	IRB does not want reported
002-101	9-Aug-18	Informed Consent	Subject was consented using ICF v13-Jun-2018 Revised 19-Jun-2018. Subject should have consented using ICF v30-Jul-2018 Revised 30-Jul-2018.	N/A	N	IRB does not want reported

002-010	1-Aug-18	Biological Specimen	The End of Week 2 plasma cotinine sample was not placed in the freezer within the allowed time per the sample handling manual. The sample was re-collected around 19:00 and processed within the required specifications. The Sponsor was notified	NA	N	
002-011	1-Aug-18	Biological Specimen	The End of Week 2 plasma cotinine sample was not placed in the freezer within the allowed time per the sample handling manual. The sample was re-collected around 19:00 and processed within the required specifications. The Sponsor was notified	NA	N	
002-014	1-Aug-18	Biological Specimen	The End of Week 2 plasma cotinine sample was not placed in the freezer within the allowed time per the sample handling manual. The sample was re-collected around 19:00 and processed within the required specifications. The Sponsor was notified	NA	N	
002-017	1-Aug-18	Biological Specimen	The End of Week 2 plasma cotinine sample was not placed in the freezer within the allowed time per the sample handling manual. The sample was re-collected around 19:00 and processed within the required specifications. The Sponsor was notified	NA	N	

002-018	1-Aug-18	Biological Specimen	The End of Week 2 plasma cotinine sample was not placed in the freezer within the allowed time per the sample handling manual. The sample was re-collected around 19:00 and processed within the required specifications. The Sponsor was notified	NA	N	
002-021	1-Aug-18	Biological Specimen	The End of Week 2 plasma cotinine sample was not placed in the freezer within the allowed time per the sample handling manual. The sample was re-collected around 19:00 and processed within the required specifications. The Sponsor was notified	NA	N	
002-023	1-Aug-18	Biological Specimen	The End of Week 2 plasma cotinine sample was not placed in the freezer within the allowed time per the sample handling manual. The sample was re-collected around 19:00 and processed within the required specifications. The Sponsor was notified	NA	N	
002-028	1-Aug-18	Biological Specimen	The End of Week 2 plasma cotinine sample was not placed in the freezer within the allowed time per the sample handling manual. The sample was re-collected around 19:00 and processed within the required specifications. The Sponsor was notified	NA	N	

002-142	8-Oct-18	Subject Compliance	Subject did not return 3 packs of VLN Non-Menthol at the End of Week 2 visit. Subject was Early Terminated.	NA	N	
002-159	3-Nov-18	Subject Compliance	Subject did not return 1 empty pack of VLN Non-Menthol at the End of Week 2 visit.	NA	N	
002-213	3-Nov-18	Subject Compliance	Subject did not return 1 empty pack of VLN Menthol at the End of Week 2 visit.	NA	N	
002-220	3-Nov-18	Subject Compliance	Subject did not return 8 empty packs of VLN Non-Menthol at the End of Week 2 visit.	NA	N	
002-142	15-Oct-18	Subject Compliance	Subject did not return multiple contact attempts and unable to complete Follow-up phone call.	NA	N	
002-170	1-Dec-18	Biological Specimen	Subject had a 24 hour urine void placed in the collection container for Subject 002-168 compromising the urine collection for both subjects.		Y	
002-168	1-Dec-18	Biological Specimen	Subject had a 24 hour urine void placed in their collection container from Subject 002-170 compromising the urine collection for both subjects.		Y	
002-253	12-Nov-18	Informed Consent	Subject did not initial and date Healthcare Provider box on page 19 of Informed Consent.	NA	N	
002-061	14-Nov-18	Informed Consent	Subject did not initial and date Healthcare Provider box on page 19 of Informed Consent.	NA	N	

002-065	15-Nov-18	Informed Consent	Subject did not initial and date Healthcare Provider box on page 19 of Informed Consent.	NA	N	